Yes my mistake. $46 was his price target initiated last Oct 21st with the stock trading around $39. I still think the Oppenheimer analyst left a lot of money on the table. This is a multi-year growth story.
This stock has endured a perfect storm of the HP ghost, two successive rounds of reduced guidance, and an industry slow-down amidst the weak capital spending environment. Management will have had ample time to prepare a positive presentation spin for next week's conference call...
I can understand that possible new market entrants could cause some customer pause, but waiting until the end of 2016 and more likely 2017 is a long time to delay internal 3D development plans. I think the slow capital spending environment as evidenced by flat GDP growth is causing a slow-down that could pick up in the second half of this year.
By twisting the arm of the WHO to label Roundup a carcinogen, Monsanto will seek non-selective herbicide alternatives by way of Syngenta. The science-challenged goons thought they found a novel way to render GMOs useless, but instead Monsanto will continue to grow and dominate the AG industry as more and more farmers embrace its yield enhancing technology.
Yes, and much of the book value is the goodwill from its IP. Any large company that wants a turnkey solution to entering the promising 3D market could take these guys out for $3 billion or so. Private equity could come in also and take the cash, while levering up the balance sheet and slash excess operating expenses.
Management should repurchase 5 million shares. The $500 million cash on hand is going to attract unwanted takeover advances. At $60 per share, management will be forced to acquiesce.
April 28 (Reuters) - Merck & #$%$ Tuesday said the U.S. Food and Drug Administration has again declined to approve Bridion, its drug to reverse the effects of muscle relaxants used in surgery, until the agency receives more data on allergic reactions to the product.
Roger Perlmutter, Merck's research chief, told analysts on a conference call that the FDA wants to receive and examine more data on "hypersensitivity" to the drug, whose chemical name is sugammadex and is sold in more than 60 countries.
The FDA has repeatedly refused to approve the drug in recent years, largely due to concerns about potentially dangerous allergic reactions to the product.
Right on cue, Cannacord publishes a downgrade report citing concerns about slowing core sales growth and the HP disruption - despite the fact that HP has no product offering other than phantomware. This same analyst had a $150 price target on the stock several months ago. No value add...
The attending nurse just made an announcement over the intercom that you are late for your shuffleboard game at noon today in the courtyard.
Wow, impressive that you're at your CRT desktop this early after the drinking binge last night. Nice work pal! Always be closing...
The analysts are mere croupiers in this game. They encourage you to trade rather than seek investment in quality companies for long-term appreciation. They add no value as a whole. They ride the momentum crowd and hedge funds like the casinos rake in Asian punters with pretty women and cocktails.
Really lame to blame currency and #$%$ - Oil? Come on, sales are weak and the company is losing money on a gaap basis. Swap into SSYS.